The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index; 210 of the 306 sources its claims cite were checked for support.
Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients
Open accessAbstract
Osteosarcoma (OS) is a type of bone cancer that is derived from primitive mesenchymal cells typically affecting children and young adults. The current standard of treatment is a combination of neoadjuvant chemotherapy and surgical resection of the cancerous bone. Post-resection challenges in bone regeneration arise. To determine the appropriate amount of bone to be removed, preoperative imaging techniques such as bone and CT scans are employed. To prevent local recurrence, the current standard of care suggests maintaining bony and soft tissue margins from 3 to 7 cm beyond the tumor. The amount of bone removed in an OS patient leaves too large of a deficit for bone to form on its own and requires reconstruction with metal implants or allografts. Both methods require the bone to heal, either to the implant or across the allograft junction, often in the setting of marrow-killing chemotherapy. Therefore, the issue of bone regeneration within the surgically resected margins remains an important challenge for the patient, family, and treating providers. Mesenchymal stem/stromal cells (MSCs) are potential agents for enhancing bone regeneration post tumor resection. MSCs, used with scaffolds and growth factors, show promise in fostering bone regeneration in OS cases. We spotlight two MSC types—bone marrow-derived (BM-MSCs) and adipose tissue-derived (ASCs)—highlighting their bone regrowth facilitation and immunomodulatory effects on immune cells like macrophages and T cells, enhancing therapeutic outcomes. The objective of this review is two-fold: review work demonstrating any ability of MSCs to target the deranged immune system in the OS microenvironment, and synthesize the available literature on the use of MSCs as a therapeutic option for stimulating bone regrowth in OS patients post bone resection. When it comes to repairing bone defects, both MB-MSCs and ASCs hold great potential for stimulating bone regeneration. Research has showcased their effectiveness in reconstructing bone defects while maintaining a non-tumorigenic role following wide resection of bone tumors, underscoring their capability to enhance bone healing and regeneration following tumor excisions.
Overview
CoChat Summary
TL;DR
This narrative review argues that mesenchymal stem/stromal cells (MSCs), especially bone marrow-derived MSCs (BM-MSCs) and adipose tissue-derived stem cells (ASCs), may promote bone regeneration after osteosarcoma (OS) tumor excision while also modulating macrophages and T cells. However, MSC effects are context-dependent, can be pro-tumorigenic, and require further safety and delivery optimization before therapeutic use.
Key findings
- MSCs can exert both pro- and anti-tumorigenic effects; without modulation, the net effect appears pro-tumorigenic, but priming, drug loading, or MSC-derived extracellular vesicles (EVs) may support anti-tumor therapy. For example, IFN-γ priming transiently upregulates MHC-I and MHC-II, and MSC EVs carrying miRNAs such as miR-16-5p, miR-3940-5p, miR-4461, and miR-15a can reduce metastatic potential or suppress tumor growth, angiogenesis, and invasion.
- BM-MSCs and ASCs show promise for bone regeneration after OS resection. In clinical reports, scaffold-free ASCs in three OS patients produced adequate bone regrowth at 54, 27, and 48 months with no prolonged inflammation or neoplastic growth; two patients receiving 3D osteogenic ASC implants showed osteogenesis without oncological side effects short-term (within 3 months) and long-term (up to 4 years). In another study, all eight patients treated with BM-MSCs in fibrin clots regained limb function at average follow-ups of 6.7 and 76 months, with no excessive tissue growth or tumor development.
- Safety data are mixed. MSC transplantation/infusion in humans is described as safe in some studies: 226 patients receiving human platelet lysate-expanded MSCs showed no malignant transformation over a mean follow-up of 11 months, and chromosomal abnormalities in culture-expanded MSCs were linked to senescence rather than tumorigenesis. However, animal studies showed MSC infusion can promote OS growth and pulmonary metastasis via CCL5, CXCR4/VEGF, and IL-6/STAT3 signaling; anti-IL-6 receptor antibodies halted the pro-tumor effects of tumor extracellular vesicle-educated MSCs.
- MSC immunomodulation is bidirectional: MSCs can polarize M1 macrophages toward an M2 anti-inflammatory phenotype, impair T cell responses, and increase Tregs, but can also promote macrophage/T cell activation and CD8+ cytotoxic T cell function while suppressing Tregs. CD146+ and CD106+ MSC subpopulations are highlighted as having higher immunomodulatory potency.
Methods
- Narrative review with a two-fold objective: review work on MSC ability to target the deranged immune system in the OS microenvironment, and synthesize literature on MSCs for stimulating bone regrowth in OS patients after bone resection.
- Evidence discussed includes in vitro studies, in vivo animal models such as nude mice and OS xenograft models, and clinical studies/case reports involving BM-MSCs or ASCs with scaffolds, growth factors, drug loading, or EVs.
- Main analysis is qualitative synthesis of mechanisms, MSC types, bone regeneration strategies, immunomodulatory effects, and safety considerations; no systematic search strategy, quality appraisal, or meta-analysis is described.
Limitations
- The paper states that further research is needed to fully understand mechanisms of action, optimize MSC delivery methods, and evaluate long-term safety and efficacy. It also lists safety/efficacy challenges in MSC manufacturing, including replacing animal-derived media with regulatory-compliant media, ensuring lack of malignant transformation via genetic stability testing, choosing local versus systemic delivery, and optimizing MSC dose (up to 5 × 10^6 cells/kg of body mass or more).
- The paper notes that MSC function is context-dependent, influenced by tissue origin and the administered tissue microenvironment; the literature is mixed on whether BM-MSCs or ASCs have superior osteogenic potential, and unknown TME effects could subvert MSCs toward pro-tumorigenic activity. It also states that only a limited number of cell-based strategies have been adopted in clinical practice, and none are definitive for delayed/non-union or bone regrowth after tumor excision.
- Evident from the text: as a narrative review, it lacks a systematic search, formal risk-of-bias assessment, or meta-analysis, and many conclusions rely on preclinical models and small clinical series.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
136 Valid · 4 Not valid · 26 Not checked · 20 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“As a result, MSCs have the potential to enhance a pro-tumor microenvironment [25].”
§ Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients > 1. MSC and the Tumor Microenvironment > 1.2. Immunomodulatory Properties of MSCs
What the sources say
- Supportedcites [25] Harrell, C.R., Volarevic, A., Djonov, V.G., Jovicic, N., and Volarevic, V. (2021). Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity. Int. J. Mol. Sci., 22. source
Section 2 describes MSCs promoting an immunosuppressive tumor microenvironment that weakens anti-tumor immunity and supports tumor growth. Section 3 also notes their pro-tumorigenic potential while emphasizing that their effects depend on local conditions. Page numbers are not provided in our copy. (LLM, conf=0.92)
states a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A higher level of T cell infiltration is indicative of a better prognosis, whereas a macrophage-predominant infiltration correlates with a worse prognosis [1].”
§ Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients > 1. MSC and the Tumor Microenvironment > 1.1. Harnessing Macrophages and T Cells in the Tumor Microenvironment for Cancer Elimination
What the sources say
- Supportedcites [1] Gonzalez, 2018, Roles of the immune system in cancer: From tumor initiation to metastatic progression, Genes Dev. source
The T cells section states that high T-cell infiltration is associated with favorable prognosis across several cancers. The Macrophages section also reports that high levels of tumor-associated macrophages correlate with poor prognosis, supporting the contrast in the citing sentence. (LLM, conf=0.93)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, in primary OS, heterogenous TAMs displaying an intermediate phenotype between M1 and M2 have been associated with anti-metastatic effects [4,5].”
§ Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients > 1. MSC and the Tumor Microenvironment > 1.1. Harnessing Macrophages and T Cells in the Tumor Microenvironment for Cancer Elimination
What the sources say
- Supportedcites [4] Cersosimo, F., Lonardi, S., Bernardini, G., Telfer, B., Mandelli, G.E., Santucci, A., Vermi, W., and Giurisato, E. (2020). Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy. Int. J. Mol. Sci., 21. source
The Introduction states that heterogeneous TAMs with an intermediate M1–M2 phenotype have been observed in primary osteosarcoma and associated with anti-metastatic activity. This directly supports the attributed claim. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [5] Buddingh, 2011, Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents, Clin. Cancer Res. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, it has been shown that native CD8+ T cells play an immunomodulatory role, more specifically in patients with primary OS [8,9].”
§ Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients > 1. MSC and the Tumor Microenvironment > 1.1. Harnessing Macrophages and T Cells in the Tumor Microenvironment for Cancer Elimination
What the sources say
- Partly supportedcites [8] Tsukahara, 2006, Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5, Cancer Sci. sourceExperimental — accuracy not yet measured
The Results section ('Relationship between HLA class I expression and T-cell infiltration in osteosarcoma tissues') documents that CD8+ T cells were found in all 20 osteosarcoma specimens, so the presence of native CD8+ T cells in primary OS is supported. However, the Discussion only 'suggest[s] that the class I-restricted cytotoxic T lymphocyte pathway plays a major role in immune surveillance of patients with osteosarcoma who undergo multidrug chemotherapy protocols' — a hedged inference drawn from HLA class I expression and survival, not a demonstrated immunomodulatory function of CD8+ T cells; the same Discussion notes the relationship between CD8+ infiltration and HLA class I expression was not statistically significant (P = 0.12, Results). The citing sentence therefore states as established what this source only suggests, and attributes a functional 'immunomodulatory role' that the paper does not itself measure. (LLM, conf=0.70)
- Partly supportedcites [9] Wang, 2016, T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities, Front. Immunol. sourceExperimental — accuracy not yet measured
The ‘Unmodified CD8+ T Lymphocytes’ section says evidence suggests cytotoxic CD8+ T cells have a leading role in immune surveillance in patients with osteosarcoma. It does not specifically establish that role in patients with primary osteosarcoma, and its wording is more tentative than ‘has been shown.’ (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As the tumor progresses, the TME induces the TAMs to polarize from an M1 to an M2 phenotype, which is pro-tumorigenic [1].”
§ Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients > 1. MSC and the Tumor Microenvironment > 1.1. Harnessing Macrophages and T Cells in the Tumor Microenvironment for Cancer Elimination
What the sources say
- Supportedcites [1] Gonzalez, 2018, Roles of the immune system in cancer: From tumor initiation to metastatic progression, Genes Dev. source
The Macrophages section says anti-tumor macrophages show M1-like polarization during carcinogenesis and that, as tumors progress, the TME elicits a protumorigenic M2-like polarization of TAMs. This supports the citing sentence as a paraphrase. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
96 more claims · 73 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 32
- It may state two separate claims as one. 60
- Borderline: one of the tests for a substantial claim is unclear. 1
- The quote only partly states this claim. 1
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
TGF-β and BMP Signaling in Osteoblast Differentiation and Bone Formation
Chen, G., Deng, C., & Li, Y.-P. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.2929 · Cited by 1,756
Caplan, A. I., & Correa, D. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.06.008 · Cited by 1,682
Macrophage Polarization States in the Tumor Microenvironment
Boutilier, A. J., & Elsawa, S. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136995 · Cited by 1,631
Waterman, R. S., Tomchuck, S. L., Henkle, S. L., & Betancourt, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010088 · Cited by 1,238
Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow
De Ugarte, D. A., Morizono, K., Elbarbary, A., Alfonso, Z., Zuk, P. A., Zhu, M., Dragoo, J. L., Ashjian, P., Thomas, B., Benhaim, P., et al. (2003) · Cells Tissues Organs · doi:10.1159/000071150 · Cited by 1,173
TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation
Tang, Y., Wu, X., Lei, W., Pang, L., Wan, C., Shi, Z., Zhao, L., Nagy, T. R., Peng, X., Hu, J., et al. (2009) · Nature Medicine · doi:10.1038/nm.1979 · Cited by 1,165
Cited by
Kostadinova, M., Raykovska, M., Simeonov, R., Lolov, S. R., & Mourdjeva, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040287 · Cited by 42
Li, J., Bai, Y., Zhang, H., Chen, T., & Shang, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1445555 · Cited by 27
Dehkordi, M. J., Bahrami, A., Abbasi, M. S., Mokhtari, M. A., Laybidi, F. H., Roosefid, A., Abari, A. H., & Mehr, M. Y. (2024) · Coatings · doi:10.3390/coatings14121522 · Cited by 12
Adaptive smart hydrogels driving precision bone healing in pathological contexts
Huang, H., Xiao, T., Li, Y., Ning, C., Tan, G., & Zhou, L. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114617 · Cited by 13
Hao, J., Yu, X., Tang, K., Ma, X., Lu, H., & Wu, C. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.06.016 · Cited by 10
Metadata
- Authors
- Baron, M., Drohat, P., Crawford, B., Hornicek, F. J., Best, T. M., & Kouroupis, D.
- Affiliations
- University of Miami (US)
- Corresponding author
- Kouroupis, Dimitrios
- ORCID
- Venue
- Bioengineering
- Publisher
- MDPI AG
- Published
- 2023-10-13
- Volume
- 10
- Issue
- 10
- Pages
- 1187
- ISSN
- 2306-5354 (ISSN-L)
- PMC
- PMC10604230
- OpenAlex
- W4387615496
- Cited by
- 19
- References
- 127
- Citations by year
- 2026: 9 · 2025: 3 · 2024: 7
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Bioengineering (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (5R21AR080388-02)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Physical Sciences › Engineering › Biomedical Engineering › Bone Tissue Engineering Materials
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Keywords
- osteosarcoma, mesenchymal stem cells, bone regeneration, immunomodulation, bone marrow-derived mesenchymal stem cells, adipose-derived stem cells, tumor resection, bone defect repair, tumor microenvironment, macrophages, T cells, neoadjuvant chemotherapy, bone marrow
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
